Gapping down
In reaction to disappointing earnings/guidance: DAKT -12.2%, LE -7.3%, ADPT -4.9%, ASNA -4.8%, WDAY -2.4%, TIVO-1.3%
Select EU financial related names showing weakness: RBS -4.2%, BCS -2.4%, DB -2.1%, LYG -1.9%, SAN -1.7%, CS-1.7%, HSBC -1.1%
Select copper mining stocks trading lower: RIO -2.8%, BBL -2.2%, BHP -2.1%, FCX -1.7%
Other news: APHB -24.6% (prices offering of 2,127,660 shares of common stock and warrants to purchase up to an aggregate of 1,063,830 shares of common stock), BABA -3.5% (SoftBank (SFTBY) to reduce its stake in Alibab to ~28%; BABA to purchase from SoftBank $2 bln BABA shares), BMRN -3% (BioMarin withdraws its Kyndrisa Marketing Authorization Application from the European Medicines Agency), FRC -2.4% (to sell 2.5 mln shares of its common stock in an underwritten public offering)
Analyst comments: NKE -2.9% (downgraded to Equal-Weight from Overweight at Morgan Stanley), EMC -1% (downgraded to Neutral from Buy at UBS), CELG -1% (downgraded to Neutral from Buy at BTIG Research).
In reaction to disappointing earnings/guidance: DAKT -12.2%, LE -7.3%, ADPT -4.9%, ASNA -4.8%, WDAY -2.4%, TIVO-1.3%
Select EU financial related names showing weakness: RBS -4.2%, BCS -2.4%, DB -2.1%, LYG -1.9%, SAN -1.7%, CS-1.7%, HSBC -1.1%
Select copper mining stocks trading lower: RIO -2.8%, BBL -2.2%, BHP -2.1%, FCX -1.7%
Other news: APHB -24.6% (prices offering of 2,127,660 shares of common stock and warrants to purchase up to an aggregate of 1,063,830 shares of common stock), BABA -3.5% (SoftBank (SFTBY) to reduce its stake in Alibab to ~28%; BABA to purchase from SoftBank $2 bln BABA shares), BMRN -3% (BioMarin withdraws its Kyndrisa Marketing Authorization Application from the European Medicines Agency), FRC -2.4% (to sell 2.5 mln shares of its common stock in an underwritten public offering)
Analyst comments: NKE -2.9% (downgraded to Equal-Weight from Overweight at Morgan Stanley), EMC -1% (downgraded to Neutral from Buy at UBS), CELG -1% (downgraded to Neutral from Buy at BTIG Research).